Literature DB >> 22920059

Assessing the safety of influenza immunization during pregnancy: the Vaccine Safety Datalink.

Elyse O Kharbanda1, Gabriela Vazquez-Benitez, Wei X Shi, Heather Lipkind, Allison Naleway, Beth Molitor, Leslie Kuckler, Avalow Olsen, James D Nordin.   

Abstract

The influenza vaccine can reduce maternal and neonatal morbidity and mortality and thus is recommended for all pregnant women. However, concerns regarding safety of influenza vaccine remain a barrier to vaccination. We describe ongoing analyses of influenza vaccine safety during pregnancy within the Vaccine Safety Datalink that includes the evaluation of acute events, adverse pregnancy and birth outcomes, and congenital anomalies. In addition, we highlight unique challenges and strategies for the study of vaccine safety among pregnant women with the use of large linked databases.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22920059     DOI: 10.1016/j.ajog.2012.06.073

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

1.  The National Vaccine Advisory Committee: reducing patient and provider barriers to maternal immunizations: approved by the National Vaccine Advisory Committee on June 11, 2014.

Authors: 
Journal:  Public Health Rep       Date:  2015 Jan-Feb       Impact factor: 2.792

2.  Individual and Neighborhood Factors Associated With Failure to Vaccinate Against Influenza During Pregnancy.

Authors:  Ousseny Zerbo; G Thomas Ray; Lea Zhang; Kristin Goddard; Bruce Fireman; Alyce Adams; Saad Omer; Martin Kulldorff; Nicola P Klein
Journal:  Am J Epidemiol       Date:  2020-11-02       Impact factor: 4.897

3.  The Centers for Disease Control and Prevention's public health response to monitoring Tdap safety in pregnant women in the United States.

Authors:  Pedro L Moro; Michael M McNeil; Lakshmi Sukumaran; Karen R Broder
Journal:  Hum Vaccin Immunother       Date:  2015-09-17       Impact factor: 3.452

4.  Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population.

Authors:  Lakshmi Sukumaran; Natalie L McCarthy; Rongxia Li; Eric S Weintraub; Steven J Jacobsen; Simon J Hambidge; Lisa A Jackson; Allison L Naleway; Berwick Chan; Biwen Tao; Julianne Gee
Journal:  Vaccine       Date:  2015-07-23       Impact factor: 3.641

5.  Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes.

Authors:  Elyse O Kharbanda; Gabriela Vazquez-Benitez; Heather S Lipkind; Nicola P Klein; T Craig Cheetham; Allison Naleway; Saad B Omer; Simon J Hambidge; Grace M Lee; Michael L Jackson; Natalie L McCarthy; Frank DeStefano; James D Nordin
Journal:  JAMA       Date:  2014-11-12       Impact factor: 56.272

6.  Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father.

Authors:  Louise C Kenny; Douglas B Kell
Journal:  Front Med (Lausanne)       Date:  2018-01-04

Review 7.  A systematic review of adverse events following immunization during pregnancy and the newborn period.

Authors:  T Roice Fulton; Divya Narayanan; Jan Bonhoeffer; Justin R Ortiz; Philipp Lambach; Saad B Omer
Journal:  Vaccine       Date:  2015-09-26       Impact factor: 3.641

8.  Respiratory distress in the neonate: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data.

Authors:  Leigh R Sweet; Cheryl Keech; Nicola P Klein; Helen S Marshall; Beckie N Tagbo; David Quine; Pawandeep Kaur; Ilia Tikhonov; Muhammad Imran Nisar; Sonali Kochhar; Flor M Muñoz
Journal:  Vaccine       Date:  2017-12-04       Impact factor: 3.641

9.  Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study.

Authors:  Akeem Yusuf; Victoria Chia; Fei Xue; Daniel D Mikol; Lisa Bollinger; Charles Cangialose
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-09-21       Impact factor: 2.890

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.